Acriptega 50mg/300mg/300mg (90 Tablets) – HIV-1 Management in Nigeria

Acriptega is a fixed-dose combination (FDC) antiretroviral medication used to manage HIV-1 infection in adults and adolescents. Often referred to as the TLD regimen, it combines three potent active ingredients into a single, once-daily pill to simplify treatment and improve long-term health outcomes.

The 90-tablet pack is specifically designed for Multi-Month Dispensing (MMD), providing a convenient 3-month supply. This reduces the frequency of pharmacy visits and supports better adherence to your treatment plan.

Composition and Active Ingredients

Acriptega contains a combination of three antiretroviral drugs:

• Dolutegravir (50mg): An integrase inhibitor (INSTI) that prevents the virus from replicating.
• Lamivudine (300mg): A nucleoside reverse transcriptase inhibitor (NRTI).
• Tenofovir Disoproxil Fumarate (300mg): A nucleotide reverse transcriptase inhibitor (NtRTI).

Why is the TLD Regimen Preferred?

The TLD combination is recognized by the Nigerian National HIV Treatment Guidelines as a first-line treatment. It is known for its high genetic barrier to resistance and fewer side effects compared to older regimens.

How to Take Acriptega

For optimal results, take one tablet daily at the same time every day. You can take it with or without food. It is crucial not to skip doses, as consistency is key to maintaining viral suppression and preventing drug resistance.

If you are unsure about your dosage or how to incorporate Acriptega into your routine, please speak with a GoMed pharmacist for professional guidance.

Important Storage Information

Acriptega is sensitive to moisture. Always keep the bottle tightly closed and do not remove the desiccant (drying agent) from the bottle. Store in a cool, dry place.

Side Effects

While most people tolerate Acriptega well, some may experience mild side effects such as headache, insomnia, or nausea. These symptoms often improve as your body adjusts to the medication. If you experience severe reactions, consult your healthcare provider immediately.